Yoo et al.1818 Yoo JH, Kim SI, Chung JW, et al. Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia. Korean J Anesthesiol. 2018;71:440-6. 2018 Korea |
100 |
Elective surgery |
Sevoflurane or desflurane |
Ap 80 mg + Palono 0.075 mg vs. Palono 0.075 mg |
41 vs. 44 |
41 vs. 44 |
52.4 ± 11.4 vs. 52.1 ± 12.0 |
86.2 ± 56.1 vs. 89.1 ± 60.0 |
128.5 ± 56.1 vs. 131.5 ± 65.9 |
Fentanyl-based IV-PCA |
No |
De Morais et al.1919 De Morais LC, Sousa AM, Flora GF, et al. Aprepitant as a fourth antiemetic prophylactic strategy in high-risk patients: a double-blind, randomized trial. Acta Anaesthesiol Scand. 2018;62:483-92. 2018 Brazil |
66 |
Laparoscopic intermediate procedures to abdominal or pelvic cancer |
Propofol epidural anesthesia |
Ap 80 mg + Ondan 4-8 mg + dexamethasone 4-8 mg vs placebo + Ondan 4-8 mg + dexamethasone 4-8 mg |
34 vs. 32 |
34 vs. 32 |
60.5 (31.87) Vs. 50.5 (19,77) |
437.5 (131, 610) vs. 367.5 (145, 600) |
N/A |
Tramadol 50 mg + dipyrone 2g |
No |
Ham et al.2020 Ham SY, Shim YH, Kim EH, et al. Aprepitant for antiemesis after laparoscopic gynaecological surgery: a randomised controlled trial. Eur J Anaesthesiol. 2016;33:90-5. 2016 Korea |
110 |
Laparoscopic gynecological surgery |
Sevoflurane |
Ap 80 mg + Ondan 4 mg vs placebo + Ondan 4 mg |
55 vs. 55 |
55 vs .55 |
40 (22-55) vs. 42 (23-61) |
N/A |
N/A |
Fentanyl IV |
No |
Kakuta et al.1010 Kakuta N, Kume K, Hamaguchi E, et al. The effects of intravenous fosaprepitant and ondansetron in the prevention of postoperative nausea and vomiting in patients who underwent lower limb surgery: a prospective, randomized, double-blind study. J Anesth. 2015;29:836-41. 2015 Japan |
38 |
Lower limb surgery |
Sevoflurane or desflurane |
Fosaprepitant 150 mg vs. Ondan 4 mg |
19 vs. 19 |
11 vs. 13 |
61 ± 11 vs. 56 ± 16 |
171 ± 47 vs. 183 ± 67 |
242 ± 55 vs. 264 ± 72 |
Diclofenac sodium 25 mg pentazocine 15mg loxoprofen 60mg celecoxib 100 mg |
No |
Soga et al.99 Soga T, Kume K, Kakuta N, et al. Fosaprepitant versus ondansetron for the prevention of postoperative nausea and vomiting in patients who undergo gynecologic abdominal surgery with patient-controlled epidural analgesia: a prospective, randomized, double-blind study. J Anesth. 2015;29:696-701. 2015 Japan |
44 |
Gynecologic abdominal surgery |
Sevoflurane, epidural anesthesia with fentanyl |
Fosaprepitant 150 mg vs. Ondan 4 mg |
24 vs. 20 |
24 vs. 20 |
52 ± 11 vs 52 ± 11 |
209 ± 96 vs. 198 ± 82 |
246 ± 94 vs. 239 ± 86 |
Epidural anesthesia with fentanyl |
No |
Long et al.2121 Long JB, Galdi L, Hentz JG, et al. Prevention of postoperative nausea and vomiting in elective hysterectomy: a prospective, randomized, placebo controlled outcomes trial of aprepitant NK-1 receptor antagonist. Open J Anesthesiol. 2014;4:301-7. 2014 USA |
94 |
Elective hysterectomy |
Sevoflurane |
Ap 40 mg + dexamethasone 8 mg + Ondan 4 mg vs. placebo + dexamethasone 8 mg + Ondan 4 mg |
35 vs. 59 |
35 vs. 59 |
60 ± 12 vs. 53 ± 12 |
153 ± 64 vs. 159 ± 81 |
N/A |
N/A |
No |
Sinha et al.2222 Sinha AC, Singh PM, Williams NW, et al. Aprepitant’s prophylactic efficacy in decreasing postoperative nausea and vomiting in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2014;24:225-31. 2014 USA |
124 |
Bariatric surgery |
Sevoflurane or desflurane |
Ap 80 mg + Ondan 4 mg vs. placebo + Ondan 4 mg |
64 vs. 60 |
42 vs. 39 |
43.09 ± 12.45 vs. 43.20 ± 12.70 |
153.05 ± 43.82 vs. 141.97 ± 41.80 |
N/A |
Fentanyl IV or morphine IV |
No |
Tsutsumi et al.88 Tsutsumi YM, Kakuta N, Soga T, et al. The effects of intravenous fosaprepitant and ondansetron for the prevention of postoperative nausea and vomiting in neurosurgery patients: a prospective, randomized, double-blinded study. Biomed Res Int. 2014;2014:307025. 2014 Japan |
64 |
Elective craniotomy |
Propofol |
fosaprepitant 150 mg vs. ondansetron 4 mg |
32 vs. 32 |
17 vs. 21 |
62 ± 10 vs. 58 ± 14 |
366 ± 137 vs. 403 ± 197 |
460 ± 138 vs. 513 ± 166 |
Diclofenac sodium 25 mg pentazocine 15 mg loxoprofen 60mg |
No |
Moon et al.2323 Moon HY, Baek CW, Choi GJ, et al. Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomized trial. BMC Anesthesiol. 2014;14:68. 2014 Korea |
93 |
Laparoscopic gynecologic surgery |
Desflurane |
Ap 40 mg vs. Palono 0.075 mg |
46 vs. 47 |
46 vs. 47 |
37.9 ± 11.1 vs. 37.6 ± 8.0 |
71.5 ± 37.7 vs. 79.2 ± 42.2 |
N/A |
Nefopam 20 mg and automated IV-PCA with fentanyl 20 µg.kg-1
|
No |
Lim et al.2424 Lim CS, Ko YK, Kim YH, et al. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting. Korean J Anesthesiol. 2013;64:212-7. 2013 Korea |
90 |
Elective rhinolaryngo-logical surgery |
Desflurane |
Ap 125 mg + Ondan 4 mg vs. Ap 80 mg + Ondan 4 mg vs. Ondan 4mg |
26 vs. 28 vs. 24 |
6 vs. 10 vs. 6 |
41 ± 12 vs. 45 ± 12 vs. 42 ± 12 |
55 ± 32 vs. 83 ± 72 vs. 62 ± 32 |
77 ± 31 vs. 105 ± 73 vs. 84 ± 33 |
Ketorolac 30 mg |
No |
Vallejo et al.2525 Vallejo MC, Phelps AL, Ibinson JW, et al. Aprepitant plus ondansetron compared with ondansetron alone in reducing postoperative nausea and vomiting in ambulatory patients undergoing plastic surgery. Plast Reconstr Surg. 2012;129:519-26. 2012 USA |
150 |
Ambulatory plastic surgery |
Sevoflurane |
Ap 40 mg + Ondan 4 mg vs. placebo + Ondan 4 mg |
75 vs. 75 |
70 vs. 70 |
60.5 (31.87) vs. 50.5 (19,77) |
122.9 ± 73.3 vs. 117.4 ± 65.4 |
164.3 ± 80.1 vs. 153.2 ± 70.1 |
Fentanyl, morphine hydromorohine, oxycodone ketorolac, meperidine acetaminophen, ibuprofen |
No |
Altorjay et al.2626 Altorjay A, Melson T, Chinachoit T, et al. Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study. Arch Surg. 2011;146:201-6. 2011 USA |
456 |
Laparoscopic gynecologi-cal surgery |
Sevoflurane |
Caso 50 mg + Ondan 4 mg vs. Placebo + Ondan 4 mg |
227 vs. 229 |
227 vs. 229 |
44.4 ± 12.19 vs. 44.8 ± 12.44 |
87.7 ± 50.39 vs. 92.1 ± 56.96 |
N/A |
N/A |
Yes |
Lee et al.2727 Lee SJ, Lee SM, Kim SI, et al. The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone. Korean J Anesthesiol. 2012;63:221-6. 2012 Korea |
84 |
Gynecological surgery |
Desflurane |
Ap 80 mg + Ramo 0.3 mg vs. Ramo 0.3 mg |
42 vs. 42 |
42 vs. 42 |
43.8 ± 8.2 vs. 43.6 ± 10.4 |
113.4 ± 61.6 vs. 124.1 ± 48.7 |
145.0 ± 62.3 vs. 158.8 ± 48.9 |
IV-PCA with fentanyl 21 µg.h-1
|
No |
Gan et al.2828 Gan TJ, Gu J, Singla N, et al. Rolapitant Investigation Group. Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial. Anesth Analg. 2011;112:804-12. 2011 USA |
619 |
Elective open abdominal surgery |
Sevoflurane or desflurane or isoflurane |
Placebo vs. Rola 5 mg vs. Rola 20 mg vs. Rola 70 mg vs. Rola 200 mg vs. Ondan 4 mg |
103 vs. 103 vs. 102 vs. 103 vs. 104 vs. 104 |
103 vs. 103 vs. 102 vs. 103 vs. 104 vs. 104 |
45.8 ± 10.1 vs. 44.6 ± 10.1 vs. 47.1 ± 12.8 vs 44.1 ± 10.1 vs. 47.4 ± 10.9 vs. 47.9 ± 12.6 |
209 ± 96 vs. 198 ± 82 |
2.2 ± 1.0 vs. 2.2 ± 1.0 vs. 2.2 ± 1.1 vs 2.1 ± 1.9 vs. 2.0 ± 0.9 vs. 2.3 ± 1.1 |
N/A |
Yes |
Habib et al.2929 Habib AS, Keifer JC, Borel CO, et al. A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy. Anesth Analg. 2011;112:813-8. 2011 USA |
104 |
Craniotomy |
Isoflurane |
Ap 40 mg + dexamethasone 10 mg vs. Ondan 4 mg + dexamethasone 10 mg |
51 vs. 53 |
28 vs. 30 |
51 ± 13 vs. 48 ± 13 |
180 (130, 223) vs. 179 (128, 213) |
N/A |
Fentanyl IVoral oxycodone oral acetaminophen |
No |
Singla et al.3030 Singla NK, Singla SK, Chung F, et al. Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. Anesthesiology. 2010;113:74-82. 2010 USA |
702 |
Laparotomic gynecologic surgical procedure or laparoscopic cholecyst-ectomy |
Sevoflurane or desflurane |
Caso 0 mg + Ondan 4 mg vs. Caso 50 mg + Ondan 4 mg vs. Caso 100 mg + Ondan 4 mg vs. Caso 150 mg + Ondan 4 mg vs. Caso 150 mg |
140 vs. 140 vs. 140 vs. 140 vs. 142 |
140 vs. 140 vs. 140 vs. 140 vs. 142 |
39.3 ± 8.15 vs. 38.1 ± 8.24 vs. 39.5 ± 8.58 vs. 39.3 ± 7.84 vs. 38.5 ± 8.33 |
77.2 ± 43.28 vs. 77.0 ± 49.87 vs. 80.5 ± 47.92 vs. 77.8 ± 43.74 vs. 79.1 ± 51.76 |
N/A |
N/A |
Yes |
Diemunsch et al.44 Diemunsch P, Gan TJ, Philip BK, et al. Aprepitant-PONV Protocol 091 International Study Group. Single-dose aprepitant vs. ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. Br J Anaesth. 2007;99:202-11. 2007 USA |
866 |
Open abdominal surgery |
Volatile anesthesia |
Ap 40 mg vs. Ap 125 mg vs. Ondan 4 mg |
303 vs. 304 vs. 285 |
273 vs. 274 vs. 257 |
46 ± 11 vs. 46 ± 11 vs. 45 ± 11 |
N/A |
2.0 ± 1.0 vs. 1.9 ± 1.0 vs. 1.8 ± 0.9 (h) |
N/A |
Yes |
Gan et al.55 Gan TJ, Apfel CC, Kovac A, et al. Aprepitant-PONV Study Group. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg. 2007;104:1082-9. 2007 USA |
766 |
Open abdominal surgery |
Volatile anesthesia |
Ap 40 mg vs. Ap 125 mg vs. Ondan 4 mg |
261 vs. 252 vs. 253 |
245 vs. 238 vs. 239 |
46 ± 11.2 vs. 44 ± 9.4 vs. 45 ± 11.2 |
N/A |
2.0 ± 1.0 vs. 2.0 ± 1.0 vs. 2.2 ± 1.2 (h) |
N/A |
Yes |